Glaucoma procedures rose 6.2 percent over Q1-2017.
Companies posted revenues totaling $8.2 billion.
More than half of surgeons polled by Market Scope indicated they do not anticipate a significant impact.
He told a Senate committee that he believes his department can end the rebates that drug manufacturers negotiate with pharmacy benefit managers.
The drugmaker is fighting several legal battles over its Restasis patents, but it cut the product’s sales force, expecting loss of protection.
The device is custom designed to match the patient’s natural iris color.
The software allows objective monitoring of retinal and vascular changes caused by disease progression or treatment.
The company also announced the start of a clinical trial for the enVista trifocal.
The home-use medical device is designed to stimulate and rejuvenate the meibomian glands.
The headset is designed to map retinal defects and display images on sighted portions of the retina.
The segment has seen recent US launches of Vyzulta, Rhopressa, and preservative-free formulations.
The segment is expected to grow at a rate of 4.8 percent over the next five years.
The work was led by Zhou Xingtao at Fudan University.
Other companies raised $34.2 million, bringing the total for the past month to $184.2 million.
The next-generation device will be installed in late 2018.
The technique could be used to ensure an unlimited supply of corneas, the university said.
The company plans to file an NDA in the US in the second half of 2019.
You are not currently logged in.
©2018 Market Scope
Lost your Password